Sipai Health Technology (0314) H2 2023 earnings summary

Executive summary

• FY2023 revenue rose 14.4% YoY to RMB4,712.1m and gross profit rose 22.9% to RMB414.7m; IFRS net loss narrowed to RMB246.7m from RMB1,371.8m.

• Continued organic growth and efficiency measures supported double-digit revenue and gross-profit growth; workforce declined to 3,096 from 3,210.

Financial highlights

• Revenue was RMB4,712.1m, up 14.4% YoY; gross profit was RMB414.7m, up 22.9%.

• IFRS net loss narrowed 82.0% to RMB246.7m from RMB1,371.8m; adjusted net loss, excluding preferred-share fair-value changes, share-based compensation and listing expenses, was RMB150.1m versus RMB258.7m.

• Reported selling and marketing expenses fell to RMB292.3m from RMB332.9m; administrative expenses fell to RMB347.8m from RMB575.0m; R&D expenses fell to RMB45.9m from RMB62.7m.

• Other income and gains increased 27.1% to RMB76.5m, mainly on higher interest income.

Outlook and guidance

• Strategic ambition is to advance digital healthcare and develop an integrated health management network linking patients, providers, pharmaceutical companies and payers.

• Management expects liquidity needs to be met through cash and cash equivalents and remaining net proceeds from the Global Offering.